tolvaptan has been researched along with Disease Models, Animal in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (7.41) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 5 (18.52) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chang, WH; Lu, HY; Shih, CC; Wu, TC | 1 |
| Fujigaki, Y; Hayama, Y; Ishizawa, K; Sakai, K; Shibata, S; Tamura, Y; Ueno, M; Wang, Q; Yamazaki, O | 1 |
| Bai, Y; Cao, D; Han, P; Tang, Y; Wang, J; Wang, X; Wang, Z | 1 |
| Alvear-Perez, R; Bonnet, D; De Mota, N; Estéoulle, L; Flahault, A; Girault-Sotias, PE; Iturrioz, X; Keck, M; Llorens-Cortes, C; Ramanoudjame, SM | 1 |
| Ando, F; Kagechika, H; Kondo, Y; Mori, S; Morimoto, T; Nomura, N; Rai, T; Sasaki, S; Sohara, E; Uchida, S; Yui, N | 1 |
| Li, G; Liu, R; Ma, Z; Wang, W; Yuan, M; Zhang, K; Zhang, Y | 1 |
| Beaudoin, JJ; Bezençon, J; Brock, WJ; Brouwer, KLR; Cao, Y; Mizuno, K; Roth, SE | 1 |
| Chen, Z; Feng, H; Guo, P; Jiang, Z; Li, Y; Liu, X; Tan, Q; Zhou, J | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Miura, K; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamazaki, T; Yoshiyama, M | 1 |
| Torra, R | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| Bellevicine, C; Bisesti, V; Buonocore, P; Cappellaio, F; De Falco, V; Federico, S; Pisani, A; Riccio, E; Russo, L; Sabbatini, M; Troncone, G | 1 |
| Arima, H; Banno, R; Fujisawa, H; Goto, M; Iwama, S; Izumida, H; Kiyota, A; Nakashima, K; Ochiai, H; Ogawa, K; Oiso, Y; Suga, H; Sugimura, Y; Suzuki, H; Takagi, H; Takeuchi, S | 1 |
| Harris, PC; Hommerding, CJ; Hopp, K; Torres, VE; Wang, X; Ye, H | 1 |
| Cornec-Le Gall, E; Le Meur, Y | 1 |
| Akahoshi, Y; Fujiki, H; Ikeda, T; Iwanaga, Y; Miyazaki, S; Morooka, H; Watanabe, H | 1 |
| Egami, N; Kakigi, A; Takeda, T; Yamasoba, T | 1 |
| Eguchi, A; Hirotani, S; Iwasaku, T; Mano, T; Masuyama, T; Naito, Y; Okuhara, Y | 1 |
| Boerrigter, G; Burnett, JC; Cataliotti, A; Costello-Boerrigter, LC; Harty, GJ | 1 |
| Ambrosy, A; Gheorghiade, M; Goldsmith, SR | 1 |
| Fujiki, H; Nakamura, S; Nakayama, S; Onogawa, T; Sakamoto, Y; Yamamura, Y | 1 |
| Fujiki, H; Miyazaki, T; Ohmoto, K; Sakamoto, Y; Yamashita, T | 1 |
| Akahoshi, Y; Fujiki, H; Iwanaga, Y; Miyazaki, S; Morooka, H; Nakano, Y; Takase, T; Tamaki, Y | 1 |
| Fujiki, H; Hanatani, A; Iwao, H; Izumi, Y; Nakamura, Y; Osada-Oka, M; Shimada, K; Shiota, M; Yamashita, N; Yamazaki, T; Yoshiyama, M | 1 |
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
| Fujiki, H; Miyazaki, T; Mori, T; Nakamura, S; Yamamura, Y | 1 |
5 review(s) available for tolvaptan and Disease Models, Animal
| Article | Year |
|---|---|
[Treatment of autosomal dominant polycystic kidney disease].
Topics: Adult; Aged; Animals; Benzazepines; Disease Models, Animal; Female; Glomerular Filtration Rate; Humans; Hypertension, Renal; Kidney; Male; Middle Aged; Models, Biological; Molecular Targeted Therapy; Organ Size; Polycystic Kidney, Autosomal Dominant; Renal Replacement Therapy; Renin-Angiotensin System; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases; TRPP Cation Channels; Young Adult | 2014 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Management; Disease Models, Animal; Drugs, Investigational; Epithelial Cells; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Mice; Models, Biological; Multicenter Studies as Topic; Polycystic Kidney, Autosomal Dominant; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Renin-Angiotensin System; Signal Transduction; Somatostatin; Tolvaptan; TOR Serine-Threonine Kinases | 2014 |
Tolvaptan for the treatment of heart failure: a review of the literature.
Topics: Animals; Benzazepines; Clinical Trials as Topic; Consensus; Disease Models, Animal; Diuresis; Diuretics; Heart Failure; Humans; Hyponatremia; Tolvaptan; Toxicity Tests; Treatment Outcome | 2011 |
Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Diuresis; Diuretics; Dogs; Dose-Response Relationship, Drug; Heart Failure; Humans; Hyponatremia; Polycystic Kidney Diseases; Rats; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2007 |
22 other study(ies) available for tolvaptan and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Tolvaptan reduces angiotensin II-induced experimental abdominal aortic aneurysm and dissection.
Topics: Angiotensin II; Animals; Aorta, Abdominal; Aortic Aneurysm, Abdominal; Apolipoproteins E; Disease Models, Animal; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Knockout, ApoE; Tolvaptan | 2022 |
Upregulation of renal Na-K-2Cl cotransporter 2 in obese diabetes mellitus via a vasopressin receptor 2-dependent pathway.
Topics: Animals; Aquaporin 2; Diabetes Mellitus, Experimental; Disease Models, Animal; Kidney; Male; Mice; Obesity; Receptors, Vasopressin; Signal Transduction; Solute Carrier Family 12, Member 1; Tolvaptan; Up-Regulation; Uromodulin | 2020 |
Tolvaptan treatment of cystine urolithiasis in a mouse model of cystinuria.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Cystine; Cystinuria; Disease Models, Animal; Female; Male; Mice; Tolvaptan; Urinary Calculi; Urolithiasis | 2021 |
A metabolically stable apelin-17 analog decreases AVP-induced antidiuresis and improves hyponatremia.
Topics: Amino Acid Sequence; Animals; Apelin; Apelin Receptors; Arginine Vasopressin; Blood Glucose; Blood Pressure; Cell Line; Colforsin; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Diuresis; Electrolytes; Half-Life; Hyponatremia; Kidney Tubules, Collecting; Male; Mice; Models, Biological; Myocardial Contraction; Peptides; Phosphorylation; Rats, Sprague-Dawley; Tolvaptan | 2021 |
AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Topics: A Kinase Anchor Proteins; Amino Acid Sequence; Animals; Aquaporin 2; Arginine Vasopressin; Benzazepines; Benzhydryl Compounds; Cell Line, Transformed; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Insipidus, Nephrogenic; Disease Models, Animal; Epithelial Cells; Gene Expression Regulation; Humans; Kidney Tubules, Collecting; Male; Mice, Inbred C57BL; Osmolar Concentration; Phenols; Protein Binding; Receptors, Vasopressin; Tolvaptan; Water | 2018 |
Beneficial effects of tolvaptan on atrial remodeling induced by chronic intermittent hypoxia in rats.
Topics: Action Potentials; Animals; Atrial Fibrillation; Atrial Remodeling; Chronic Disease; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Heart Atria; Heart Rate; Hypoxia; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase 9; MicroRNAs; Rats, Sprague-Dawley; Signal Transduction; Tolvaptan | 2018 |
Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Hepatobiliary Elimination; Humans; In Vitro Techniques; Kidney; Liver; Male; Perfusion; Polycystic Kidney, Autosomal Dominant; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptors, Cell Surface; Tolvaptan | 2019 |
Tolvaptan attenuated brain edema in experimental intracerebral hemorrhage.
Topics: Animals; Biological Transport; Blood-Brain Barrier; Brain; Brain Edema; Cerebral Hemorrhage; Disease Models, Animal; Male; Occludin; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Tolvaptan | 2019 |
Tolvaptan attenuates left ventricular fibrosis after acute myocardial infarction in rats.
Topics: Acute-Phase Reaction; Animals; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Male; Myocardial Infarction; Rats; Rats, Wistar; Tolvaptan; Ventricular Dysfunction, Left; Ventricular Remodeling | 2013 |
Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats.
Topics: Animals; Benzazepines; Cyclic AMP; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Kidney; Male; MAP Kinase Signaling System; Polycystic Kidney Diseases; Rats; Rats, Inbred Strains; Rats, Mutant Strains; Rats, Sprague-Dawley; Sirolimus; Tolvaptan; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Minocycline prevents osmotic demyelination associated with aquaresis.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Aquaporin 4; Astrocytes; Behavior, Animal; Benzazepines; Biomarkers; Brain; Chemokines; Cytokines; Cytoprotection; Deamino Arginine Vasopressin; Demyelinating Diseases; Disease Models, Animal; Diuresis; Hyponatremia; Intracranial Hemorrhages; Male; Matrix Metalloproteinases; Minocycline; Neuroprotective Agents; Osmosis; Rats, Sprague-Dawley; Saline Solution, Hypertonic; Sodium; Therapeutics; Time Factors; Tolvaptan; Water-Electrolyte Balance | 2014 |
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model.
Topics: Animals; Antidiuretic Agents; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Line, Tumor; Cell Membrane; Cyclic AMP; Deamino Arginine Vasopressin; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microsatellite Repeats; Models, Genetic; Polycystic Kidney, Autosomal Dominant; Somatostatin; Tolvaptan; TRPP Cation Channels | 2015 |
Effects of Long-term Blockade of Vasopressin Receptor Types 1a and 2 on Cardiac and Renal Damage in a Rat Model of Hypertensive Heart Failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertension; Hypertrophy, Left Ventricular; Kidney; Kidney Diseases; Male; Piperidines; Quinolones; Rats, Inbred Dahl; Receptors, Vasopressin; Time Factors; Tolvaptan; Ventricular Function, Left; Ventricular Remodeling | 2015 |
Dehydration effects of a V2 antagonist on endolymphatic hydrops in guinea pigs.
Topics: Administration, Oral; Administration, Topical; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Endolymphatic Hydrops; Endolymphatic Sac; Female; Guinea Pigs; Meniere Disease; Osmolar Concentration; Receptors, Vasopressin; Tolvaptan; Vasopressins; Water-Electrolyte Balance | 2016 |
Long-term administration of tolvaptan increases myocardial remodeling and mortality via exacerbation of congestion in mice heart failure model after myocardial infarction.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Heart Failure; Lung Diseases; Male; Mice; Mice, Inbred C57BL; Mortality; Myocardial Infarction; Random Allocation; Time Factors; Tolvaptan; Ventricular Remodeling | 2016 |
Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure.
Topics: Aldosterone; Animals; Benzazepines; Blood Pressure; Disease Models, Animal; Dogs; Drug Therapy, Combination; Glomerular Filtration Rate; Heart Failure; Male; Natriuretic Agents; Natriuretic Peptide, Brain; Receptors, Vasopressin; Renal Circulation; Tolvaptan; Water-Electrolyte Balance | 2010 |
Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Atrial Natriuretic Factor; Benzazepines; Blood Pressure; Body Weight; Chlorides; Disease Models, Animal; Diuretics; Dogs; Furosemide; Heart Failure; Kidney; Male; Potassium; Renin; Sodium; Tolvaptan | 2011 |
Anti-edematous effects of tolvaptan in experimental rodent models.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Carrageenan; Disease Models, Animal; Diuretics; Edema; Foot Diseases; Histamine; Male; Permeability; Rats; Rats, Sprague-Dawley; Skin Diseases, Vascular; Sodium; Tolvaptan | 2011 |
Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure.
Topics: Administration, Oral; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Biomarkers; Blood Pressure; Disease Models, Animal; Disease Progression; Drug Administration Schedule; Heart Failure; Hormone Antagonists; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Natriuretic Peptides; Rats; Rats, Inbred Dahl; Receptors, Vasopressin; RNA, Messenger; Sodium Chloride, Dietary; Time Factors; Tolvaptan; Ultrasonography; Urination; Ventricular Dysfunction, Left; Ventricular Function, Left | 2012 |
Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Furosemide; Hemodynamics; Male; Myocardial Infarction; Rats; Rats, Wistar; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Tolvaptan; Treatment Outcome; Ventricular Dysfunction, Left | 2012 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |